Benzinga | Dec 17, 2020 09:15AM EST

Roth Capital Initiates Coverage On Usana Health Sciences with Buy Rating, Announces Price Target of $107

Roth Capital analyst David Bain initiates coverage on Usana Health Sciences (NYSE:USNA) with a Buy rating and announces Price Target of $107.